Ustekinumab-aekn (Selarsdi) is biosimilar to Ustekinumab (Stelara). Approved 04/16/2024
Ustekinumab-auub (Wezlana) is biosimilar to Ustekinumab (Stelara). Approved 10/31/2023
- TRADE NAME: Stelara (Centocor)
- INDICATIONS: Plaque psoriasis (moderate to severe); active psoriatic arthritis; active Crohn's disease (moderate to severe)
- CLASS: Antipsoriatic agent, Biologic, Interleukin-12/23 antagonist, Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor, Monoclonal antibody
- HALF-LIFE: 15–32 days
- FDA APPROVAL DATE: 09/25/2009
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines, Typhoid Vaccine, Yellow Fever Vaccine
- See adverse reactions attributed to class:
Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ustekinumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/26/2025
